Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04231084 · ClinicalTrials.gov registry record · Phase 4
Comparison of Vasodilator Response of Inhaled Epoprostenol and Inhaled Nitric Oxide
A Phase 4 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 115
- Enrollment target
NCT04231084 is a Phase 4 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 115 participants.
The verdict
NCT04231084, a Phase 4 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 115 participants
- Enrollment target
Study Summary
The overarching goal of this study is to examine the acute vasoreactive response to both inhaled nitric oxide and inhaled epoprostenol across both traditionally and non-traditionally interrogated phenotypes in PH, and to further characterize the relationship of vasoreactivity to disease severity and PH phenotype.
Interventions
- DRUG Vasodilator testing (Inhaled Nitric Oxide)
- DRUG Vasodilator testing (Inhaled Epoprostenol)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2021-01-15 |
| Est. Completion | 2024-08-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04231084
The ClinicalTrials.gov registry entry for NCT04231084 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vasodilator testing (Inhaled Nitric Oxide) is the first listed.
NCT04231084 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04231084 about?
NCT04231084 is a clinical study titled "Comparison of Vasodilator Response of Inhaled Epoprostenol and Inhaled Nitric Oxide". The overarching goal of this study is to examine the acute vasoreactive response to both inhaled nitric oxide and inhaled epoprostenol across both traditionally and non-traditionally interrogated phenotypes in PH, and to further characterize the relationship of vasoreactivity to disease severity and...
What is the current status of trial NCT04231084?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 115 participants. The study started on 2021-01-15. Estimated completion is 2024-08-01.
What interventions are being tested in trial NCT04231084?
The interventions under investigation include: Vasodilator testing (Inhaled Nitric Oxide) (DRUG), Vasodilator testing (Inhaled Epoprostenol) (DRUG).
Who is sponsoring clinical trial NCT04231084?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.